COVID-19 pandemic and eating disorders: What impact on specific and general psychopathology?

Autor: E. Barone, F. Marciello, G. Cascino, G. Abbate-Daga, S. Anselmetti, M. Baiano, M. Balestrieri, S. Bertelli, B. Carpiniello, G. Castellini, G. Corrivetti, S. De Giorgi, A. Favaro, C. Gramaglia, E. Marzola, F. Monaco, M.G. Oriani, P. Federica, M. Rania, C. Renna, V. Ricca, P. Salvo, C. Segura-Garcia, F. Scarabel, P. Todisco, U. Volpe, P. Zeppegno, P. Monteleone, A.M. Monteleone

Publikováno v: European Psychiatry, Vol 64, Pp S114-S115 (2021)

Introduction The coronavirus disease 2019 (COVID-19) pandemic and the resulting containment measures, such as “lockdown” and “social distancing”, have had important consequences on people’s mental and physical health. Objectives We aimed

Externí odkaz: https://doaj.org/article/458c51fa51934bee8f10c7e3a06f4164

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-world evidence from a European cohort study of patients with treatment resistant depression:Healthcare resource utilization

Autor: S. De Giorgi, G. Degraeve, Gianluca Rosso, Pilar Sierra, V. Perez Sola, K. Heerlein, S. Rathod, Thomas Frodl, Albino J. Oliveira-Maia, Y. Kambarov, B. Rive, Christian Otte, J. Morrens, S. Mulhern Haughey, W. Hagedoorn, Antonio Vita, Allan H. Young

Publikováno v: Heerlein, K, De Giorgi, S, Degraeve, G, Frodl, T, Hagedoorn, W, Oliveira-Maia, A J, Otte, C, Perez Sola, V, Rathod, S, Rosso, G, Sierra, P, Vita, A, Morrens, J, Rive, B, Mulhern Haughey, S, Kambarov, Y & Young, A H 2022, ' Real-world evidence from a European cohort study of patients with treatment resistant depression : Healthcare resource utilization ', Journal of Affective Disorders, vol. 298, pp. 442-450 . https://doi.org/10.1016/j.jad.2021.11.004
JOURNAL OF AFFECTIVE DISORDERS
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Journal of affective disorders 298, Part A 442-450 (2022). doi:10.1016/j.jad.2021.11.004 special issue: "Special Issue on Corona Virus / Edited by Allan Young, Ron Acierno, Xiang Yang Zhang"

Journal of affective disorders 298, Part A 442-450 (2022). doi:10.1016/j.jad.2021.11.004 special issue: "Special Issue on Corona Virus / Edited by Allan Young, Ron Acierno, Xiang Yang Zhang"
Published by Elsevier Science, Amsterdam [u.a.]

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4228d67af279356c15b0441b2eba1ca8
https://kclpure.kcl.ac.uk/ws/files/175765192/Real_world_evidence_from_HEERLEIN_Publishedonline17November2021_GOLD_VoR_CC_BY.pdf

T.07.2 LONGITUDINAL EVALUATION OF GUT MICROBIOME AFTER FECAL MICROBIOTA TRANSPLANTATION FOR ERADICATING CLOSTRIDIOIDES DIFFICILE INFECTION

Autor: S. Porcari, N. Karcher, M. Puncochár, M. Valles Colomer, G. Quaranta, S. Bibbo, S. De Giorgi, L. Masucci, M. Sanguinetti, A. Gasbarrini, G. Cammarota, N. Segata, G. Ianiro

Publikováno v: Digestive and Liver Disease. 54:S142-S143

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0dee987647b1cfa6a7240c646f7ba0ee
https://doi.org/10.1016/s1590-8658(22)00435-2

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial

Autor: Pignata, S. Lorusso, D. Joly, F. Gallo, C. Colombo, N. Sessa, C. Bamias, A. Salutari, V. Selle, F. Frezzini, S. De Giorgi, U. Pautier, P. Bologna, A. Orditura, M. Dubot, C. Gadducci, A. Mammoliti, S. Ray-Coquard, I.L. Zafarana, E. Breda, E. Favier, L. Ardizzoia, A. Cinieri, S. Largillier, R. Sambataro, D. Guardiola, E. Lauria, R. Pisano, C. Raspagliesi, F. Scambia, G. Daniele, G. Perrone, F. Joly, F. Gallo, C. Colombo, N. Sessa, C. Bamias, A. Salutari, V. Selle, F. Frezzini, S. Bologna, A. Orditura, M. Dubot, C. Gadducci, A. Mammoliti, S. Zafarana, E. Breda, E. Favier, L. Ardizzoia, A. Cinieri, S. Largillier, R. Sambataro, D. Guardiola, E. Lauria, R. Pisano, C. Raspagliesi, F. Scambia, G. Daniele, G. Perrone, F. MITO16b/MANGO-OV2/ENGOT-ov17 Investigators

Background: Bevacizumab is approved in combination with chemotherapy for the treatment of ovarian cancer, either in first-line therapy or for patients with recurrent disease not previously treated with the same drug. We aimed to test the value of con

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::811670d53f30c1b27036e8a852073d28
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3120032